Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Will Apogee Therapeutics’ APEX data shift competitive dynamics against Dupixent and Ebglyss?
Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.
LGM Pharma’s $15m U.S. manufacturing expansion signals a deeper shift away from import dependence in pharma supply chains
LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.
Triana Biomedicines tests degradation-first approach in ALK positive lung cancer with TRI-611
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
Gene therapy gains ground in bladder cancer as NCCN strengthens Ferring Pharmaceuticals’ ADSTILADRIN recommendation
ADSTILADRIN gains NCCN upgrade in bladder cancer. Discover what this means for gene therapy adoption, clinical use, and future NMIBC treatment trends.
Cathy Tie’s Origin Genomics targets germline gene correction under US IRB oversight
Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.
Oral Pompe therapy S-606001 moves to Phase 2 as Shionogi expands rare disease focus
Shionogi’s S-606001 enters global Phase 2 as the first oral GYS1 inhibitor tested as an add-on to ERT in late-onset Pompe disease. Read the analysis.
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France’s AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
Novartis acquires SNV4818 from Synnovation in $3bn deal to reclaim ground in mutant PI3Ka breast cancer space
Novartis acquires SNV4818, a next-gen mutant-selective PI3Ka inhibitor, for up to $3bn. What this means for the HR+/HER2- breast cancer market. Read now.
Will pediatric KONFIDENT-KID data accelerate KalVista’s sebetralstat approval in hereditary angioedema?
KalVista’s sebetralstat pediatric trial data heads to Madrid. What it means for the HAE on-demand market and a 2026 FDA filing. Read the analysis.